Wockhardt Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/a5nyd6dcjchn30gh87s6c12h.pdf

Key Takeaways


ZAYNICH: The Lead Asset

Habil Khorakiwala: "if I have to get more value for my proposition, I have to be very serious of creating my own organization as an alternative. So that -- it's not that for people come and give me a rate. But if I have expectation higher than that, I have to say that I have an alternative available if I believe this is a value we will."

Miqnaf: The India Launch Underway

Murtaza Khorakiwala: "after 30 years there is a new antibiotic in the macrolide class which is there... Wockhardt has introduced India discovered, India R&D, India developed clinical trial done in India, Maa product for the Indian market which we will now take outside India into the rest of the world after 35 years"

Insulin & Biosimilar Opportunity


Financial Turnaround & Cost Discipline


Pipeline & Other Assets

Habil Khorakiwala: "So they are totally in sync, because scientists know much more of the molecule because they have lived with the molecule for last 10-15 years. So whatever they plan to transfer the knowledge to medical or commercial people it will not be same level. So we are keeping them as a part of overall business development, so that our scientific profile, whether in India or US or anywhere will be second to none"

Guidance & Commitments

CommitmentSpecificsTimeline
ZAYNICH US filingFile with USFDAComing quarter
ZAYNICH US launchApproval takes 9-12 months from filingMiddle of next year
ZAYNICH India approvalFiled March 2025; approval expectedBeginning of next year
ZAYNICH India launch3-4 months post-approvalMiddle of next year
ZAYNICH Europe & EM filingFile in H2 this yearH2 this year
ZAYNICH Europe & EM launchDependent on approval timeH2 next year
Insulin capacity doublingDouble capacity and put up new facilityNext 24 months
Biotech capacity doublingDouble capacityNext 24-36 months
Business doublingDouble the overall businessNext 3 years
Miqnaf promotion expansionExpand to consulting physicians, ENTs, pediatriciansAfter 6 months from launch
Miqnaf specialist restrictionPromotion restricted to specialists, not GPsNext 3-4 years
R&D spendingContinue at USD 200-250 mn or moreOngoing
US CEO hirePotential hire for own US organizationNext few months

Key Metrics

MetricQ4 FY25
Revenue₹3,033 cr, +5% YoY
EBITDA₹418 cr, +67% YoY
EBITDA margin14%, expanded 500 bps from 9%
Net debt₹64 cr, reduced from ₹882 cr in FY22
Net debt to equity0.01%
Cash available₹600 cr
Equity₹4,600 cr, up from ₹3,600 cr
India branded business growth+4% YoY
UK business growth+8% YoY
Emerging markets business growth+10% YoY
Biosimilar business growth+20% YoY
EMROK market share~10% in India
EMROK cumulative patients treated100,000
ZAYNICH global Phase 3 superiority20% over existing treatment
ZAYNICH Phase 2 efficacy vs carbapenem-resistant organisms>90%
ZAYNICH compassionate-use lives saved51 in last 1.5 years
Miqnaf Phase 3 efficacy96.7%
Miqnaf treatment duration3 days, vs 5–7 days for conventional therapies
ZAYNICH global addressable patients~0.2 cr annually
ZAYNICH US and Europe addressable market$7 bn, 371,000 cases
ZAYNICH India addressable market₹17,000 cr, ~0.1 cr cases
Miqnaf India addressable market₹10,800 cr, 9.6 cr prescriptions
Diabetes portfolio emerging-market opportunity$3 bn
R&D spend on new drug discovery$200–250 mn annually, expected to continue
QIP raised₹1,000 cr